• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Hunt Ronald

    1/6/25 5:07:03 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HUNT RONALD

    (Last) (First) (Middle)
    C/O RALLYBIO CORPORATION
    234 CHURCH STREET, SUITE 1020

    (Street)
    NEW HAVEN CT 06510

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Rallybio Corp [ RLYB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option (Right to Buy) $0.95 01/02/2025 A 73,571 (1) 01/02/2035 Common Stock 73,571 $0.7(2) 73,571 D
    Explanation of Responses:
    1. The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.
    2. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.
    Remarks:
    By: /s/ Michael Greco, Attorney-in-Fact 01/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RLYB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rallybio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Rallybio from Buy to Neutral

      4/9/25 8:36:28 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by JP Morgan

      JP Morgan downgraded Rallybio from Overweight to Neutral

      5/15/24 7:39:44 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by Jefferies with a new price target

      Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

      2/7/24 6:42:56 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Financials

    Live finance-specific insights

    See more
    • Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

      -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

      12/20/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

      – On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. "We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe th

      5/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage bi

      4/29/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

      – RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the inability of the R

      4/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Uden Stephen

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:30:54 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ryder Steven

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:29:06 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Lieber Jonathan I

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:27:18 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      11/12/24 10:34:15 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rallybio Corporation

      SC 13G - Rallybio Corp (0001739410) (Subject)

      7/30/24 9:06:36 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      7/30/24 12:47:55 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    SEC Filings

    See more
    • SEC Form S-8 filed by Rallybio Corporation

      S-8 - Rallybio Corp (0001739410) (Filer)

      5/9/25 4:06:03 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rallybio Corporation

      10-Q - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:22:09 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:14:12 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

      -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

      6/29/23 7:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

      -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

      3/6/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

      1/31/23 4:05:00 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care